Last reviewed · How we verify
NCT03798964
The Expression Heparanase in Term and Preterm Placentas
trial testing Placental analysis in Preterm Birth in 20 participants. Completed in 24 November 2020.
24 November 2020
Quick facts
| Lead sponsor | Hillel Yaffe Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 23 January 2019 |
| Primary completion | 24 November 2020 |
| Estimated completion | 24 November 2020 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Placental analysis
Conditions studied
- Preterm Birth — all drugs for Preterm Birth →
Sponsor
Hillel Yaffe Medical Center
Who can join
Adults 18 to 40, female only, with Preterm Birth. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM). This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) . The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03798964
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preterm Birth
Currently open trials in the same condition.
- NCT07265583 — Early Prediction of Lung Injury in Preterm Infants Score · recruiting
- NCT07305935 — Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury · NA · recruiting
- NCT07192393 — Health-Related Quality-of-Life and Household Financial and Wellbeing Impacts of Prematurity and Necrotising Enterocoliti · recruiting
- NCT06826859 — Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH) · Phase 1, PHASE2 · recruiting
- NCT07231432 — Promoting Kangaroo Care for Preterm or Low Birthweight Infants in Rural India · NA · active not recruiting
Other Hillel Yaffe Medical Center trials
Trials by the same sponsor.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07134985 — Pediatric Patients Who Leave the Emergency Department Without Treatment · recruiting
- NCT06927193 — Regional Analgesia at the Pediatric Emergency Department · recruiting
- NCT07233525 — Home-Based Language and Cognitive Intervention for Arab Toddlers in Israel · NA · not yet recruiting
- NCT07320339 — The Aim of the Study is to Examine the Variation in Blood Pressure Between an Optimal Measurement (According to Establis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03798964 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hillel Yaffe Medical Center
- Last refreshed: 28 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03798964.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing